Cyxone AB (publ) (CYXO.ST)
SEK 0.02
(0.0%)
SEK 0.02
(0.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 5.14 Million SEK | -19.55% |
| 2022 | 6.39 Million SEK | 0.0% |
| 2021 | - SEK | 0.0% |
| 2020 | - SEK | -100.0% |
| 2019 | 26.56 Thousand SEK | 2556.9% |
| 2018 | 1000.00 SEK | 0.0% |
| 2017 | - SEK | -100.0% |
| 2016 | 21 Thousand SEK | 0.0% |
| 2015 | 21 Thousand SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | - SEK | -100.0% |
| 2024 Q1 | 1.13 Million SEK | 21.04% |
| 2023 Q2 | -1.42 Million SEK | -200.0% |
| 2023 Q1 | 1.42 Million SEK | -77.67% |
| 2023 FY | 5.14 Million SEK | -19.55% |
| 2023 Q4 | 941 Thousand SEK | 0.0% |
| 2023 Q3 | - SEK | 100.0% |
| 2022 FY | 6.39 Million SEK | 0.0% |
| 2022 Q3 | - SEK | 0.0% |
| 2022 Q4 | 6.39 Million SEK | 0.0% |
| 2022 Q2 | - SEK | 0.0% |
| 2022 Q1 | - SEK | 0.0% |
| 2021 Q1 | - SEK | 0.0% |
| 2021 Q2 | - SEK | 0.0% |
| 2021 Q3 | - SEK | 0.0% |
| 2021 FY | - SEK | 0.0% |
| 2021 Q4 | - SEK | 0.0% |
| 2020 Q4 | - SEK | 0.0% |
| 2020 Q1 | - SEK | 0.0% |
| 2020 FY | - SEK | -100.0% |
| 2020 Q2 | - SEK | 0.0% |
| 2020 Q3 | - SEK | 0.0% |
| 2019 Q4 | - SEK | 0.0% |
| 2019 FY | 26.56 Thousand SEK | 2556.9% |
| 2019 Q3 | - SEK | 0.0% |
| 2019 Q2 | - SEK | 0.0% |
| 2019 Q1 | - SEK | -100.0% |
| 2018 Q1 | - SEK | 0.0% |
| 2018 FY | 1000.00 SEK | 0.0% |
| 2018 Q2 | - SEK | 0.0% |
| 2018 Q3 | - SEK | 0.0% |
| 2018 Q4 | 1000.00 SEK | 0.0% |
| 2017 Q1 | - SEK | 0.0% |
| 2017 Q2 | - SEK | 0.0% |
| 2017 FY | - SEK | -100.0% |
| 2017 Q3 | - SEK | 0.0% |
| 2017 Q4 | - SEK | 0.0% |
| 2016 Q4 | - SEK | 0.0% |
| 2016 Q1 | - SEK | 0.0% |
| 2016 FY | 21 Thousand SEK | 0.0% |
| 2016 Q2 | - SEK | 0.0% |
| 2016 Q3 | - SEK | 0.0% |
| 2015 FY | 21 Thousand SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 58.1 Million SEK | 91.14% |
| Ziccum AB (publ) | 3.74 Million SEK | -37.39% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 615.99 Million SEK | 99.164% |
| Sprint Bioscience AB (publ) | 50.48 Million SEK | 89.803% |
| Mendus AB (publ) | 28.48 Million SEK | 81.929% |
| Genovis AB (publ.) | 158.23 Million SEK | 96.747% |
| Intervacc AB (publ) | 8.01 Million SEK | 35.77% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 4.37 Million SEK | -17.695% |
| Active Biotech AB (publ) | - SEK | -Infinity% |
| Magle Chemoswed Holding AB (publ) | 170.44 Million SEK | 96.98% |
| Bio-Works Technologies AB (publ) | 43.89 Million SEK | 88.272% |
| Aptahem AB (publ) | 2.63 Million SEK | -95.693% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | 1.03 Million SEK | -397.391% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -6585.714% |
| Fluicell AB (publ) | 3.33 Million SEK | -54.224% |
| Saniona AB (publ) | 16.84 Million SEK | 69.43% |
| Lipigon Pharmaceuticals AB (publ) | 16.4 Million SEK | 68.623% |
| Biovica International AB (publ) | 7.29 Million SEK | 29.383% |
| Spago Nanomedical AB (publ) | 1.2 Million SEK | -327.93% |
| AcouSort AB (publ) | 10.55 Million SEK | 51.208% |
| Xintela AB (publ) | 78 Thousand SEK | -6500.0% |
| Abliva AB (publ) | 137 Thousand SEK | -3657.664% |
| Egetis Therapeutics AB (publ) | 57.6 Million SEK | 91.063% |
| Karolinska Development AB (publ) | 2.01 Million SEK | -155.611% |
| OncoZenge AB (publ) | 3000.00 SEK | -171500.0% |
| Amniotics AB (publ) | - SEK | -Infinity% |
| 2cureX AB (publ) | 155 Thousand SEK | -3221.29% |
| CombiGene AB (publ) | 5.54 Million SEK | 7.145% |
| Asarina Pharma AB (publ) | - SEK | -Infinity% |
| Calliditas Therapeutics AB (publ) | 1.2 Billion SEK | 99.573% |
| Camurus AB (publ) | 1.71 Billion SEK | 99.7% |
| Corline Biomedical AB | 25.03 Million SEK | 79.433% |
| IRLAB Therapeutics AB (publ) | 5.67 Million SEK | 9.334% |
| Isofol Medical AB (publ) | 721 Thousand SEK | -614.008% |
| I-Tech AB | 120.86 Million SEK | 95.741% |
| Hansa Biopharma AB (publ) | 134.09 Million SEK | 96.161% |
| ExpreS2ion Biotech Holding AB (publ) | 7.05 Million SEK | 26.979% |
| Biosergen AB | - SEK | -Infinity% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | 10.66 Million SEK | 51.729% |
| Xspray Pharma AB (publ) | - SEK | -Infinity% |
| Elicera Therapeutics AB (publ) | 11.23 Million SEK | 54.159% |
| Nanologica AB (publ) | 1.44 Million SEK | -256.757% |
| SynAct Pharma AB | - SEK | -Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | 53 Thousand SEK | -9613.208% |
| BioInvent International AB (publ) | 71.46 Million SEK | 92.796% |
| Alzinova AB (publ) | 270 Thousand SEK | -1806.667% |
| Oncopeptides AB (publ) | 35.22 Million SEK | 85.383% |
| Pila Pharma AB (publ) | 1.46 Million SEK | -251.875% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | 2.82 Million SEK | -82.424% |
| Simris Alg AB (publ) | 4.35 Million SEK | -18.236% |
| Diamyd Medical AB (publ) | 130 Thousand SEK | -3860.0% |
| Xbrane Biopharma AB (publ) | 238.72 Million SEK | 97.844% |
| Ascelia Pharma AB (publ) | - SEK | -Infinity% |
| Diagonal Bio AB (publ) | 23 Thousand SEK | -22282.609% |